Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Is There Merit for MET-Targeted Therapies in Gastroesophageal Cancer?

Mazzone M, Finisguerra V, Prenen H.

JAMA Oncol. 2018 Jan 1;4(1):131-132. doi: 10.1001/jamaoncol.2017.2725. No abstract available.

PMID:
28910432
2.

Hypoxia determines survival outcomes of bacterial infection through HIF-1alpha dependent re-programming of leukocyte metabolism.

Thompson AA, Dickinson RS, Murphy F, Thomson JP, Marriott HM, Tavares A, Willson J, Williams L, Lewis A, Mirchandani A, Dos Santos Coelho P, Doherty C, Ryan E, Watts E, Morton NM, Forbes S, Stimson RH, Hameed AG, Arnold N, Preston JA, Lawrie A, Finisguerra V, Mazzone M, Sadiku P, Goveia J, Taverna F, Carmeliet P, Foster SJ, Chilvers ER, Cowburn AS, Dockrell DH, Johnson RS, Meehan RR, Whyte MK, Walmsley SR.

Sci Immunol. 2017 Feb 10;2(8). pii: eaal2861. doi: 10.1126/sciimmunol.aal2861.

3.

Preclinical and clinical evaluation of MET functions in cancer cells and in the tumor stroma.

Finisguerra V, Prenen H, Mazzone M.

Oncogene. 2016 Oct 20;35(42):5457-5467. doi: 10.1038/onc.2016.36. Epub 2016 Mar 21. Review.

PMID:
26996670
4.

MET is required for the recruitment of anti-tumoural neutrophils.

Finisguerra V, Di Conza G, Di Matteo M, Serneels J, Costa S, Thompson AA, Wauters E, Walmsley S, Prenen H, Granot Z, Casazza A, Mazzone M.

Nature. 2015 Jun 18;522(7556):349-53. doi: 10.1038/nature14407. Epub 2015 May 18.

5.

Tumor stroma: a complexity dictated by the hypoxic tumor microenvironment.

Casazza A, Di Conza G, Wenes M, Finisguerra V, Deschoemaeker S, Mazzone M.

Oncogene. 2014 Apr 3;33(14):1743-54. doi: 10.1038/onc.2013.121. Epub 2013 Apr 22. Review.

PMID:
23604130
6.

Gene-targeting of Phd2 improves tumor response to chemotherapy and prevents side-toxicity.

Leite de Oliveira R, Deschoemaeker S, Henze AT, Debackere K, Finisguerra V, Takeda Y, Roncal C, Dettori D, Tack E, Jönsson Y, Veschini L, Peeters A, Anisimov A, Hofmann M, Alitalo K, Baes M, D'hooge J, Carmeliet P, Mazzone M.

Cancer Cell. 2012 Aug 14;22(2):263-77. doi: 10.1016/j.ccr.2012.06.028.

7.

Macrophage skewing by Phd2 haplodeficiency prevents ischaemia by inducing arteriogenesis.

Takeda Y, Costa S, Delamarre E, Roncal C, Leite de Oliveira R, Squadrito ML, Finisguerra V, Deschoemaeker S, Bruyère F, Wenes M, Hamm A, Serneels J, Magat J, Bhattacharyya T, Anisimov A, Jordan BF, Alitalo K, Maxwell P, Gallez B, Zhuang ZW, Saito Y, Simons M, De Palma M, Mazzone M.

Nature. 2011 Oct 9;479(7371):122-6. doi: 10.1038/nature10507.

8.

Sema3E-Plexin D1 signaling drives human cancer cell invasiveness and metastatic spreading in mice.

Casazza A, Finisguerra V, Capparuccia L, Camperi A, Swiercz JM, Rizzolio S, Rolny C, Christensen C, Bertotti A, Sarotto I, Risio M, Trusolino L, Weitz J, Schneider M, Mazzone M, Comoglio PM, Tamagnone L.

J Clin Invest. 2010 Aug;120(8):2684-98. doi: 10.1172/JCI42118. Epub 2010 Jul 26. Erratum in: J Clin Invest. 2011 Jul 1;121(7):2945. Mazzone, Massimilano [corrected to Mazzone, Massimiliano].

9.

Transferrin receptor 2 is frequently and highly expressed in glioblastomas.

Calzolari A, Larocca LM, Deaglio S, Finisguerra V, Boe A, Raggi C, Ricci-Vitani L, Pierconti F, Malavasi F, De Maria R, Testa U, Pallini R.

Transl Oncol. 2010 Apr;3(2):123-34.

10.

Regulation of transferrin receptor 2 in human cancer cell lines.

Calzolari A, Finisguerra V, Oliviero I, Deaglio S, Mariani G, Malavasi F, Testa U.

Blood Cells Mol Dis. 2009 Jan-Feb;42(1):5-13. doi: 10.1016/j.bcmd.2008.10.001. Epub 2008 Nov 18.

PMID:
19019709

Supplemental Content

Loading ...
Support Center